FIGURE 1 (A-B)

FIG.1A





FIG. 1B



A. Mean vs actual time, DARPin® protein #51

B. Mean vs actual time, DARPin® protein #50

C. Mean vs actual time, DARPin® protein #54

D. Mean vs actual time, DARPin® protein #53

E. Mean vs actual time, DARPin® protein #55

FIGURE 2 (A-D)

FIG. 2A




FIG. 2B




FIG. 2C



Response (RU)
100
90
80
70
60
50
40
30
20
10
0
-10
-300 -200 -100 0 100 200 300 400 500 600 700 800 900
Time (s)
64 nM
32 nM
16 nM
8 nM

FIG. 2D




SPR binding affinity to human targets
K_D [M]
10^{-7}
10^{-8}
10^{-9}
10^{-10}
10^{-11}
CD70
CD123
CD33
scCD3eg
SA
DARPin® protein #56
DARPin® protein #57


FIGURE 3 (A-C)

FIG. 3A




	EC50
TL0995	6.518
TL01026	5023
TL01027	6005
TL01028	~ 816348397
AMG330 (batch 1)	4.352
DART	5.348

FIG. 3B



	EC50
TLO1015 (parental)	1.413
TLO1029	1.972
TLO1030	4467
TLO1031	373.4
TLO1032	69277
AMG330 (batch 1)	4.352
DART	5.348


FIG. 3C



	EC50
TLO954 (parental)	1.802
TLO1034	~ 609305629
TLO1035	1005
TLO1036	36166
TLO1037	~
AMG330 (batch 1)	4.352
DART	5.348


FIGURE 4 (A-C)

FIG. 4A




	EC50
TLO995	6.8
TLO1038	127
TLO1041	1567
TLO1044	378
AMG330	6.6
DART	4.6

FIG. 4B



	EC50
TLO1029	5.8
TLO1039	23
TLO1042	155
TLO1045	46
AMG330	6.6
DART	4.6


FIG. 4C



	EC50
TLO1033	14
TLO1040	15
TIO1043	45
TLO1046	59
AMG330	6.6
DART	4.6


FIGURE 5 (A-C)

FIG. 5A




	EC50
TLO995	4.888
TLO1026	3709
TLO1027	5334
TLO1028	217668
AMG330 (batch 1)	0.7476
DART	2.258

FIG. 5B



	EC50
TLO1015 (parental)	1.678
TLO1029	0.4854
TLO1030	3819
TLO1031	139.0
TLO1032	0.3651
AMG330 (batch 1)	0.7476
DART	2.258


FIG. 5C



	EC50
TLO954 (parental)	16.21
TLO1034	~ 25382160
TLO1035	982.9
TLO1036	11629
TLO1037	1.137
AMG330 (batch 1)	0.7476
DART	2.258


FIGURE 6 (A-C)

FIG. 6A




	EC50
TLO995	10
TLO1038	257
TLO1041	2725
TLO1044	362
AMG330	7.5
DART	0.96

FIG. 6B



	EC50
TLO1029	7.8
TLO1039	55
TLO1042	229
TLO1045	44
AMG330	7.5
DART	0.96

FIG. 6C



	EC50
TLO1033	11
TLO1040	14
TLO1043	35
TLO1046	46
AMG330	7.5
DART	0.96

FIGURE 7





FIGURE 8



3PL-Fit

	EC50
N1	0.34
CD33KO	16
CD123KO	0.81
CD70KO	25
CD33/123DKO	466
CD33/70DKO	1038
CD123/70DKO	267
CD33CD123CD70TKO	23

FIGURE 9 (A-D)

FIG. 9A




FIG. 9B




FIG. 9C



DARPin® protein #29
IFNg (pg/ml)
100000
10000
1000
100
10
1
0
2
4
8
24
Time (hours)
Vehicle (PBS)
DARPin® protein #29 0.005 nM
DARPin® protein #29 0.1 nM
DARPin® protein #29 2 nM

FIG. 9D



DARPin® protein #31
IFNg (pg/ml)
100000
10000
1000
100
10
1
0
2
4
8
24
Time (hours)
Vehicle (PBS)
DARPin® protein #31 0.005 nM
DARPin® protein #31 0.1 nM
DARPin® protein #31 2 nM

FIGURE 10 (A-D)

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIGURE 11 (A-D)

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIGURE 12 (A-D)

FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIGURE 13 (A-D)

FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIGURE 14 (A-D)

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIGURE 15 (A-B)

FIG. 15A




FIG. 15B




FIGURE 16 (A-B)

FIG. 16A




FIG. 16B




FIGURE 17




FIGURE 18



CD123
KD (nM)
10
1
0.1
0.01
4.5 nM
0.30 nM
4.2 nM
N.A.
N.A.
N.A.
KD1
KD2
KD1
KD2
KD1
KD2
DARPin® protein 27
DARPin® protein 40
DARPin® protein 41

FIGURE 19





FIGURE 20 (A-B)


FIG. 20A



CD123	CD33	Ni2C
CD123	CD33	CD3 (C7v118)
CD123	CD33	CD3 (C7v119)
CD123	CD33	CD3 (C7v122)
CD123	CD33	CD3 (C7v127)

	TLO737	TLO768	TLO769	TLO772	TLO777	AMG330	Flotetuzumab
EC50	286	642	399	99	7	9	56


FIG.20B



H04	CD123	CD33	Ni2C
H04	CD123	CD33	CD3 (C7v118)
H04	CD123	CD33	CD3 (C7v119)
H04	CD123	CD33	CD3 (C7v122)
H04	CD123	CD33	CD3 (C7v127)

	TLO745	TLO800	TLO801	TLO802	TLO803	AMG330	Flotetuzumab
EC50	2475	139	1038	274	19	9	56

FIG. 20C



3-PL-Fit

	EC50
CHE1256	0.17
CHE1258	0.19
PSC466	0.26
SMA555	0.13
SMA558	0.16
SMA560	0.13
PSC465	0.36
TLO1214	0.096

FIGURE 21





FIGURE 22 (A-B)


FIG. 22A



TLO737	CD123	CD33	Ni2C
TLO768	CD123	CD33	CD3 (C7v118)
TLO769	CD123	CD33	CD3 (C7v119)
TLO772	CD123	CD33	CD3 (C7v122)
TLO777	CD123	CD33	CD3 (C7v127)

	TLO737	TLO768	TLO769	TLO772	TLO777	AMG330 CD33_CD3
EC50	322	87	2	4	20	2

FIG. 22B




H04	CD123	CD33	Ni2C
H04	CD123	CD33	CD3 (C7v118)
H04	CD123	CD33	CD3 (C7v119)
H04	CD123	CD33	CD3 (C7v122)
H04	CD123	CD33	CD3 (C7v127)

	TLO745	TLO800	TLO801	TLO802	TLO803	AMG330 CD33_CD3
EC50	3	6776	37	39	77	2

FIGURE 23 (A-B)


FIG. 23A



TLO737	CD123	CD33	Ni2C
TLO768	CD123	CD33	CD3 (C7v118)
TLO769	CD123	CD33	CD3 (C7v119)
TLO772	CD123	CD33	CD3 (C7v122)
TLO777	CD123	CD33	CD3 (C7v127)

	TLO737	TLO768	TLO769	TLO772	TLO777	AMG330 CD33_CD3
EC50	0.02	298	5	5	14	2

FIG. 23B



H04	CD123	CD33	Ni2C
H04	CD123	CD33	CD3 (C7v118)
H04	CD123	CD33	CD3 (C7v119)
H04	CD123	CD33	CD3 (C7v122)
H04	CD123	CD33	CD3 (C7v127)

	TLO745	TLO800	TLO801	TLO802	TLO803	AMG330 CD33_CD3
EC50	7335	14951	99	39	54	3

FIGURE 24 (A-B)

FIG. 24A




FIG. 24B




FIGURE 25






FIGURE 26 (A-B)

FIG. 26A



	EC50
TLO768 (C7v118)	41.80
TLO769 (C7v119)	0.6568
TLO772 (C7v122)	0.6862
TLO777 (C7v127)	11.59
TLO787	0.2057
TLO788	77.89
TLO791	4.815
TLO796	0.004617
TLO737	0.04659
MPEXT118 (CD123_DART)	0.08295
MPEXT120 (CD33-CD3 BITE)	2.677


FIG. 26B



	EC50
TLO800	[illegible]
TLO801	29.59
TLO802	11.73
TLO803	49.18
TLO745	[illegible]
MPEXT118 (CD123_DART)	0.08295
MPEXT120 (CD33-CD3 BITE)	2.677


FIGURE 27 (A-B)

FIG. 27A



	EC50
TLO768 (C7v118)	96.78
TLO769 (C7v119)	1.960
TLO772 (C7v122)	1.069
TLO777 (C7v127)	16.12
TLO787	0.04902
TLO788	[illegible]
TLO791	207.0
TLO796	52.77
TLO737	1945
MPEXT118 (CD123_DART)	0.2448
MPEXT120 (CD33-CD3 BITE)	3.879

FIG. 27B



	EC50
TLO800	~ 56313432
TLO801	38.30
TLO802	34.10
TLO803	67.96
TLO745	~ 91976
MPEXT118 (CD123_DART)	0.2448
MPEXT120 (CD33-CD3 BITE)	3.879

FIGURE 28 (A-F)

FIG. 28A




FIG.28B




FIG.28C




FIG.28D




FIG.28E




FIG.28F




FIGURE 29 (A-F)

FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D




FIG. 29E




FIG. 29F




FIGURE 30 (A-F)

FIG. 30A




FIG. 30B




FIG. 30C




FIG. 30D




FIG. 30E




FIG. 30F




FIGURE 31 (A-F)

FIG. 31A




FIG. 31B




FIG. 31C




FIG.31D




FIG. 31E




FIG. 31F




FIGURE 32 (A-F)

FIG. 32A




FIG.32B




FIG. 32C




FIG.32D




FIG. 32E




FIG. 32F




FIGURE 33 (A-F)

FIG. 33A




FIG. 33B




FIG. 33C




FIG. 33D




FIG. 33E




FIG. 33F




FIGURE 34 (A-B)

FIG. 34A




FIG. 34B




FIG. 34C




FIG. 34D




FIG. 34E




FIG. 34F




FIGURE 35 (A-F)

FIG. 35A




FIG. 35B




FIG. 35C




FIG 35D




FIG. 35E




FIG 35F




FIGURE 36 (A-F)

FIG. 36A




FIG. 36B




FIG. 36C




FIG. 36D




FIG. 36E




FIG. 36F




FIGURE 37 (A-F)

FIG. 37A




FIG. 37B




FIG. 37C




FIG. 37D




FIG. 37E




FIG. 37F




FIGURE 38 (A-B)

FIG. 38A




FIG. 38B




FIGURE 39 (A-B)

FIG. 39A




FIG. 39B




FIGURE 40




FIGURE 41




FIGURE 42 (A-C)

FIG. 42A




FIG. 42B




FIG. 42C




FIGURE 43 (A-L)

FIG. 43A




FIG. 43B




FIG. 43C




FIG. 43D




FIG. 43E




FIG. 43F




FIG. 43G




FIG. 43H




FIG 43I




FIG. 43J




FIG. 43K




FIG. 43L




FIGURE 44 (A-H)

FIG.44A




FIG.44B




FIG.44C




FIG.44D




FIG.44E




FIG.44F




FIG.44G




FIG.44H




FIGURE 45 (A-H)

FIG.45A




FIG.45B




FIG.45C




FIG.45D




FIG.45E




FIG.45F




FIG.45G




FIG.45H




FIGURE 46 (A-H)

FIG.46A




FIG.46B




FIG.46C




FIG.46D




FIG.46E




FIG.46F




FIG.46G




FIG.46H




FIGURE 47 (A-H)

FIG.47A




FIG.47B




FIG.47C




FIG.47D




FIG.47E




FIG.47F




FIG.47G




FIG.47H




FIGURE 48 (A-H)

FIG. 48A




FIG.48B




FIG.48C




FIG.48D




FIG. 48E




FIG.48F




FIG.48G




FIG.48H




FIGURE 49 (A-H)

FIG.49A




FIG.49B




FIG.49C




FIG.49D




FIG.49E




FIG.49F




FIG.49G




FIG.49H




FIGURE 50 (A-H)

FIG.50A




FIG.50B




FIG.50C




FIG.50D




FIG.50E




FIG.50F




FIG. 50G




FIG. 50H





FIGURE 51 (A-E)

FIG.51A



	EC50
DARPin® protein #58 0.005 nM	3.82
DARPin® protein #59 0.005 nM	4.85
DARPin® protein #56 0.005 nM	26.1
DARPin® protein #57 0.005 nM	10.4
DARPin® protein #60 0.005 nM	7.84
DARPin® protein #61 0.005 nM	4.57

FIG.51B



	EC50
PSC466	23.3
SMA555	10.2

FIG.51C






FIG. 51D



	EC50
CD33+CD123+CD70+	7.507
CD33+CD70+	8.798
CD123+CD70+	27.36
CD33+CD123+	20.70
CD33+	37.79
CD123+	431.4
CD70+	82.10


FIG. 51E



	EC50
CD33+CD123+CD70+	5.601
CD33+CD70+	5.634
CD123+CD70+	47.00
CD33+CD123+	11.47
CD33+	190.6
CD123+	690.7
CD70+	250.9


FIGURE 52 (A-D)

FIG.52A




	EC50
CHE1256	0.69
CHE1258	1.1
PSC466	7.1
SMA555	1.6
SMA558	1.0
SMA560	0.60

FIG.52B




	IC50
PSC466	4.564
PSC469	
TLO1323	
SMA555	1.305
TLO1221	
TLO1320	

FIG.52C



	EC50 (pM)
HSA-HSA-CD33-CD123-CD70-CD3	21.23
CD33-CD3 BiTE	1.26
CD123-CD3 DART	0.8


FIG. 52D



	EC50
CD33+CD123+CD70+	15.97
CD33+CD70+	10.05
CD123+CD70+	45.63
CD33+CD123+	18.97
CD33+	107.1
CD123+	340.0
CD70+	456.5

FIGURE 53 (A-B)

FIG. 53A



	Autologous T cells	Allogenic T cells
IC50	37.49	247.4

FIG. 53B





FIGURE 54 (A-B)

FIG. 54A



(1)Flotetuzumab

(2)DARPin® protein #57

(3)DARPin® protein #56


(4)DARPin® protein #59

(5)DARPin® protein #58

(6)DARPin® protein #61

(7)DARPin® protein #60

FIG. 54B



(1) DARPin® protein #58

(2) DARPin® protein #59

(3) DARPin® protein #56

(4) DARPin® protein #57

(5) DARPin® protein #60

(6) DARPin® protein #61

(7) Flotetuzumab

FIGURE 55




FIGURE 56




FIGURE 57 (A-F)

FIG. 57A




FIG. 57B




FIG. 57C




FIG. 57D




FIG. 57E




FIG. 57F




FIGURE 58 (A-B)

FIG. 58A




FIG. 58B



MOLM-13 tumor growth
at day 17
Tumor volume (mm3)
2500
2000
1500
1000
500
0
Vehicle
DARPin® protein #56
AMG330

FIGURE 59 (A-L)

FIG.59A




FIG. 59B




FIG. 59C




FIG.59D




FIG. 59E




FIG. 59F




FIG. 59G




FIG. 59H




FIG. 59I




FIG. 59J




FIG. 59K




FIG. 59L




FIGURE 60 (A-L)

FIG. 60A




FIG. 60B




FIG. 60C




FIG. 60D




FIG. 60E




FIG. 60F




FIG. 60G




FIG. 60H




FIG. 60I




FIG. 60J




FIG. 60K




FIG. 60L




FIGURE 61 (A-L)

FIG. 61A




FIG. 61B




FIG. 61C




FIG. 61D




FIG. 61E




FIG. 61F




FIG. 61G




FIG. 61H




FIG. 61I




FIG. 61J




FIG. 61K




FIG. 61L






FIGURE 62 (A-H)

FIG. 62A




	EC50
PSC466	53.22
SMA555	5.242
MP'EXT115 (Flotetuzumab)	2.886
MP'EXT120 (AMG330)	4.427

FIG. 62B




	EC50
PSC466	3025
SMA555	22.33
MP'EXT115 (Flotetuzumab)	1.525
MP'EXT120 (AMG330)	2.296

FIG. 62C




	EC50
PSC466	98.24
SMA555	13.57
MP'EXT115 (Flotetuzumab)	45.76
MP'EXT120 (AMG330)	18.46

FIG. 62D




	EC50
PSC466	647.9
SMA555	159.8
MP:EXT110 (Flotetuzumab)	11.33
MP:EXT120 (AMG330)	14.86

FIG. 62E




	EC50
PSC466	64.84
SMA555	1.869
MP:EXT110 (Flotetuzumab)	2.193
MP:EXT120 (AMG330)	1.895

FIG. 62F




	EC50
PSC466	933.1
SMA555	44.25
MP:EXT110 (Flotetuzumab)	4.036
MP:EXT120 (AMG330)	2.068

FIG. 62G



	EC50
PSC466	78.92
SMA555	13.35
MP[illegible]	18.62
MP[illegible]	6.314

FIG. 62H



	EC50
PSC466	301.6
SMA555	169.1
MP[illegible]	11.94
MP[illegible]	0.295

FIGURE 63




FIGURE 64




FIGURE 65




FIGURE 66



MOLM-13 tumor growth
tumor volume (mm3)
2000
1500
1000
500
0
10
15
20
day after tumor injection
Vehicle
DARPin® protein #56 at 2mg/kg
DARPin® protein #56 at 0.5mg/kg
DARPin® protein #56 at 0.2mg/kg
DARPin® protein #56 at 0.02mg/kg

FIGURE 67 A-C

FIG. 67A




FIG. 67B




FIG. 67C




FIGURE 68 A-D

FIG. 68A




FIG. 68B




FIG. 68C




FIG. 68D



TNFa level in serum
pg/ml
100
80
60
40
20
0
Vehicle
DARPin® protein #74
DARPin® protein #75
DARPin® protein #56
DARPin® protein #57
AMG330
Flotetuzumab

FIGURE 69 A-B

FIG. 69A




FIG. 69B

